AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24716637 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/day) in TT genotype
Number of subjects: 84
Study 24716637 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsupplementation) in TT genotype
Number of subjects: 84
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise cardiac index (CI)
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-diastolic pressure estimates (E/e')
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak exercise CI (multivariate analysis)
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: E/e' (multivariate analysis)
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE (multivariate analysis)
Number of subjects: 102
Study 22818784 — intervention group
Group type: EXPERIMENTAL
Intervention: LV ejection fraction at rest
Number of subjects: 102
Study 19208715 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy performed by doctors
Number of subjects: 1888
Study 19208715 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy performed by nurses
Number of subjects: 1888
Study 18159966 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment-letter intervention
Number of subjects: 320
Study 18159966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no appointment letter)
Number of subjects: 320
Study 15110095 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of PhIP (7.4 ng/g)
Number of subjects: 71
Study 15110095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of PhIP (1.7 ng/g)
Number of subjects: 71
Study 15110095 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 genotype
Number of subjects: 71
Study 15110095 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 genotype
Number of subjects: 71
Study 11808891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (36 subjects)
Number of subjects: 311
Study 11808891 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 subjects)
Number of subjects: 311
Study 9738129 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLIT (two 15-min sessions, separated by 6 hr)
Number of subjects: 10
Study 9738129 — intervention group
Group type: COMPARATOR
Intervention: CONT (30 min of exercise at 70% VO(2)max)
Number of subjects: 10
Study 9738129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SPLIT and CONT
Number of subjects: 10
Study 8056578 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (2 mg) + vitamin C (500 mg) + vitamin E (200 mg) + glutathione (200 mg)
Number of subjects: 63
Study 8056578 — intervention group
Group type: COMPARATOR
Intervention: Control group (same regimen without Azelastine)
Number of subjects: 63
Study 3202095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined restriction of thiamin, riboflavin, and vitamins B-6 and C with supplementation of other vitamins at twice the RDA.
Number of subjects: 23
Study 3202095 — intervention group
Group type: COMPARATOR
Intervention: Control group with supplementation of twice the RDA of all vitamins.
Number of subjects: 23
Study 31715039 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Number of subjects: 136
Study 31715039 — intervention group
Group type: COMPARATOR
Intervention: Routine intravenous injection procedure
Number of subjects: 136
Study 31044363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional micro-needle radiofrequency (FMR)
Number of subjects: 17
Study 31044363 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 17
Study 29267737 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education intervention
Number of subjects: 183
Study 29267737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 183
Study 26518955 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-glutamine (50 g)
Number of subjects: 33
Study 26518955 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 33
Study 24617168 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg and placebo
Number of subjects: 60
Study 24617168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 750 mg and placebo
Number of subjects: 60
Study 24617168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger 750 mg and Diclofenac 50 mg
Number of subjects: 60
Study 24617168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21566876 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) group
Number of subjects: 60
Study 21566876 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (control)
Number of subjects: 60
Study 21566876 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL group
Number of subjects: 60
Study 19571249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 3320
Study 19571249 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 3320
Study 17052502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade) treatment
Number of subjects: 47
Study 14727011 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral daily ibandronate (2.5 mg/day)
Number of subjects: 110
Study 14727011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 110
Study 14727011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11518354 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium clodronate (300 mg to 900 mg intravenously)
Number of subjects: 10
Study 11518354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 10
Study 9590668 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 177
Study 9590668 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 177
Study 9590668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 7825990 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T at 1 and 3 months (group A)
Number of subjects: 197
Study 7825990 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T at 2 and 4 months (group B)
Number of subjects: 197
Study 7825990 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T in lyophilized form at 2, 3 and 4 months (second study)
Number of subjects: 197
Study 7825990 — intervention group
Group type: COMPARATOR
Intervention: No PRP-T (group C)
Number of subjects: 197
Study 2970805 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF, 99‐126) infusion at 15 ng.kg‐1.min‐1 for 20 minutes
Number of subjects: 10
Study 2970805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 10
Study 30185428 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy‐Health Care
Number of subjects: 167
Study 30185428 — intervention group
Group type: COMPARATOR
Intervention: Attention control (weekly family supportive counseling)
Number of subjects: 167
Study 28780562 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose graft transposition procedure (AGTP)
Number of subjects: 108
Study 28780562 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 108
Study 26637169 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted strategy including feedback, educational sessions, reminders, and additional/optional improvement actions
Number of subjects: 50
Study 26637169 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive feedback strategy (providing non-anonymous comparative feedback on appropriateness of antibiotic use)
Number of subjects: 50
Study 22968306 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (15 g·d‐1)
Number of subjects: 60
Study 22968306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21362032 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus melatonin (group B)
Number of subjects: 42
Study 21362032 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus tryptophan (group C)
Number of subjects: 42
Study 21362032 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus placebo (group A)
Number of subjects: 42
Study 18781069 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse followed by a 228 microg/g F rinse
Number of subjects: 12
Study 18781069 — intervention group
Group type: COMPARATOR
Intervention: 912 microg/g F rinse
Number of subjects: 12
Study 18781069 — intervention group
Group type: COMPARATOR
Intervention: 228 microg/g F rinse
Number of subjects: 12
Study 17161060 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. beta-EPO for 3 months twice weekly, in addition to daily oral iron
Number of subjects: 40
Study 17161060 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in s.c. injections and daily oral iron
Number of subjects: 40
Study 14616408 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 3 mg kg‐1 twice daily
Number of subjects: 64
Study 14616408 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (various doses)
Number of subjects: 64
Study 14616408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11771972 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 9565125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine, 60 mg intravenously at the time of trocar insertion
Number of subjects: 70
Study 9565125 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg orally an hour before surgery
Number of subjects: 70
Study 8033760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor from essential oil of black pepper
Number of subjects: 48
Study 8033760 — intervention group
Group type: COMPARATOR
Intervention: Mint/menthol cartridge
Number of subjects: 48
Study 8033760 — intervention group
Group type: COMPARATOR
Intervention: Empty cartridge (unflavored placebo)
Number of subjects: 48
Study 2548964 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (50-80 mg/kg/day in three doses during meals)
Number of subjects: 55
Study 2548964 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (6-10 mg trimethoprim/kg/day in two doses after meals)
Number of subjects: 55
Study 7576 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone (80 to 160 mg)
Number of subjects: 17
Study 7576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined propranolol (80 to 160 mg) and phenoxybenzamine (20 to 50 mg)
Number of subjects: 17
Study 7576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with hydrochlorothiazide (50-100 mg)
Number of subjects: 17
Study 7576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with hydrochlorothiazide
Number of subjects: 17
Study 31487868 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical condition (food addiction diagnosed by a doctor)
Number of subjects: 962
Study 31487868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-diagnosed condition (target believes herself to be a food addict)
Number of subjects: 962
Study 29155873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 0
Study 26417835 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 6
Study 26417835 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 6
Study 26417835 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP)
Number of subjects: 6
Study 26417835 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study 23292595 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS
Number of subjects: 3
Study 23292595 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 3
Study 21673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - oral metronomic dosing (50 mg/day)
Number of subjects: 35
Study 21673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - single intravenous dose (1,000 mg)
Number of subjects: 35
Study 21673660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CP) - both oral and intravenous
Number of subjects: 35
Study 21673660 — intervention group
Group type: COMPARATOR
Intervention: Control group - virus only (N = 8)
Number of subjects: 35
Study 17507163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg (P600)
Number of subjects: 91
Study 17183151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 23
Study 17183151 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (80 mg/day)
Number of subjects: 23
Study 12845210 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed 3.0 mg/m² and oxaliplatin 130 mg/m² intravenously on day 1 every 3 weeks
Number of subjects: 21
Study 10831944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation at the anterior side of the isthmus (group A)
Number of subjects: 72
Study 10831944 — intervention group
Group type: COMPARATOR
Intervention: Ablation at the posterior side of the isthmus (group P)
Number of subjects: 72
Study 10831944 — intervention group
Group type: COMPARATOR
Intervention: Ablation at the posterior side of the isthmus (group P) after failure at A
Number of subjects: 72
Study 10831944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation at the anterior side of the isthmus (group A) after failure at P
Number of subjects: 72
Study 10831944 — intervention group
Group type: COMPARATOR
Intervention: Ablation at P
Number of subjects: 72
Study 9332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 6
Study 9332626 — intervention group
Group type: COMPARATOR
Intervention: Active placebo intervention
Number of subjects: 6
Study 9332626 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shifts
Number of subjects: 6
Study 8229533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (20% Intralipid at < 12 hours after birth, starting at 0.5 gm/kg and increasing to a maximum of 1.5 gm/kg, maintained through day 7)
Number of subjects: 133
Study 8229533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (20% Intralipid at < 12 hours after birth)
Number of subjects: 133
Study 8229533 — intervention group
Group type: COMPARATOR
Intervention: Control (no lipid until after day 7)
Number of subjects: 133
Study 30132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy for 24 weeks (6 hours per week)
Number of subjects: 38
Study 30132999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 30132999 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation therapy
Number of subjects: 38
Study 27149033 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation with continuation of baseline antiarrhythmic medications
Number of subjects: 259
Study 27149033 — intervention group
Group type: COMPARATOR
Intervention: Escalated antiarrhythmic drug therapy (including amiodarone and mexiletine)
Number of subjects: 259
Study 24119840 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily topical exit-site application of antibacterial honey plus standard exit-site care
Number of subjects: 371
Study 24119840 — intervention group
Group type: COMPARATOR
Intervention: Standard exit-site care plus intranasal mupirocin prophylaxis (control group)
Number of subjects: 371
Study 22539169 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (<5 h)
Number of subjects: 13
Study 22539169 — intervention group
Group type: COMPARATOR
Intervention: Control sleep (>7 h)
Number of subjects: 13
Study 21427992 — intervention group
Group type: EXPERIMENTAL
Intervention: safocid (1 g of seknidasol, 1 g of azitromycin, 150 mg of fluconasol)
Number of subjects: 128
Study 18630538 — intervention group
Group type: EXPERIMENTAL
Intervention: fu-needle
Number of subjects: 60
Study 18630538 — intervention group
Group type: COMPARATOR
Intervention: routine acupuncture
Number of subjects: 60
Study 16496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial interventions for autism
Number of subjects: 0
Study 16496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative treatment designs
Number of subjects: 0
Study 11805482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m tetrofosmin myocardial SPECT exercise and resting imaging; dosage: 370 MBq (10 mCi) during exercise, 740 MBq (20 mCi) at rest; duration: imaging performed at specified intervals after injection
Number of subjects: 75
Study 11805482 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m tetrofosmin myocardial SPECT exercise and resting imaging
Number of subjects: 75
Study 10524882 — intervention group
Group type: EXPERIMENTAL
Intervention: No scalpel approach
Number of subjects: 1429
Study 10524882 — intervention group
Group type: COMPARATOR
Intervention: Standard incision approach
Number of subjects: 1429
Study 8528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Work site smoking restrictions
Number of subjects: 20801
Study 8528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to ETS
Number of subjects: 20801
Study 8528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bothered by smokiness
Number of subjects: 20801
Study 8528716 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsafe working environment
Number of subjects: 20801
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole with isoconazole cream
Number of subjects: 90
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole with keratolytic cream
Number of subjects: 90
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole with placebo cream
Number of subjects: 90
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin with isoconazole cream
Number of subjects: 90
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin with keratolytic cream
Number of subjects: 90
Study 1657803 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin with placebo cream
Number of subjects: 90
Study 6176320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 0
Study 6176320 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nodal radiotherapy followed by chemotherapy
Number of subjects: 0
Study 6176320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy to areas of bulky disease
Number of subjects: 0
Study 6176320 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing regimen
Number of subjects: 0
Study 30954710 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback training (NFT) with feedback on auditory cortex activity
Number of subjects: 0
Study 30954710 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback (control group)
Number of subjects: 0
Study 30954710 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback training (NFT)
Number of subjects: 0
Study 28821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 45 minutes at 65% of maximal capacities
Number of subjects: 28
Study 28821320 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - remained seated
Number of subjects: 28
Study 28821320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 28
Study 28821320 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study 25618890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functional approach for 8 weeks
Number of subjects: 36
Study 25618890 — intervention group
Group type: COMPARATOR
Intervention: Usual care from coaches
Number of subjects: 36
Study 23657122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vibration and wobble board training
Number of subjects: 33
Study 21285133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 154
Study 21285133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 154
Study 21285133 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 154
Study 19720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed FEV(1)/FVC ratio of 0.70
Number of subjects: 815
Study 19720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed FEV(1)/FVC ratio of 0.75
Number of subjects: 815
Study 19720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed FEV(1)/FVC ratio of 0.80
Number of subjects: 815
Study 17927859 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 47
Study 17927859 — intervention group
Group type: COMPARATOR
Intervention: Minimal incision thoracotomy (MIT)
Number of subjects: 47
Study 15380290 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 16
Study 15380290 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 16
Study 15380290 — intervention group
Group type: COMPARATOR
Intervention: (R)-methadone
Number of subjects: 16
Study 11594259 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 0
Study 11594259 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 0
Study 9576424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 9576424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7881703 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg methylprednisolone tablet (Medrol)
Number of subjects: 14
Study 7881703 — intervention group
Group type: COMPARATOR
Intervention: 100 mg methylprednisolone intravenous formulation (Solu‐Medrol)
Number of subjects: 14
Study 2850132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg IV)
Number of subjects: 18
Study 2850132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (30 mg day‐1 for 3 months)
Number of subjects: 18
Study 2850132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18